A NuGenia Logics publication · Free to read

Tirzepatide’s Effects on Muscle and Lean Mass in Overweight Individuals

Tirzepatide, a dual glucose-dependent insulinotropic polypeptide and glucagon-like peptide-1 receptor agonist, has shown significant efficacy for weight loss in individuals with overweight and obesity. However, the implications of this weight reduction on lean mass remain ambiguous. This narrative review evaluates the current evidence regarding tirzepatide’s effects on body composition, particularly changes in lean mass and its proxy measures.

A structured literature search identified ten studies, including randomized controlled trials, observational studies, and modeling analyses, encompassing diverse populations with and without type 2 diabetes mellitus. Across these studies, tirzepatide consistently produced large, dose-dependent reductions in body weight. Notably, these reductions were primarily attributed to fat mass, although decreases in lean mass, fat-free mass, or skeletal muscle mass were observed in all studies.

The proportion of total weight loss attributable to lean mass generally ranged from 10% to 30%, which aligns with expected physiological responses to weight loss. However, substantial heterogeneity in study design, population characteristics, and body composition assessment methods limits the ability to draw definitive conclusions. Most studies relied on indirect measures such as bioelectrical impedance analysis, with limited use of dual-energy X-ray absorptiometry.

Importantly, functional outcomes were not assessed, and the clinical significance of observed lean mass reductions remains uncertain. Overall, tirzepatide appears to promote preferential fat loss, although some loss of lean mass occurs. Strategies such as resistance training and adequate protein intake may help mitigate potential adverse effects on muscle mass during treatment.

What this study does not show

This review does not establish the clinical significance of lean mass reductions associated with tirzepatide treatment.

Evidence scorecard

  • Analytic validity: Not established
  • Clinical validity: Partial
  • Clinical utility: Not established
Sponsored
Article slot — 728×90

Evidence classes are taken from source metadata — publication type and trial registration — never from opinion. How we classify · Corrections